Caris Life Sciences announced its common shares will begin trading on NYSE Texas on June 17, 2026, while continuing to list on Nasdaq under the ticker CAI. The company said the dual listing expands visibility among Texas and broader U.S. investors and reflects its strong connection to Texas, where it is headquartered and employs more than 450 people. Caris Life Sciences is a TechBio and precision medicine company that uses molecular profiling and AI to advance personalized oncology and chronic disease care. Separately, Wolfe Research analyst Mike Polark initiated coverage of CAI with a Peer Perform rating and no price target.
Caris Life Sciences, Inc. Common StockDual listing on NYSE Texas expands investor visibility and access, a positive capital markets event.